Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
NASDAQ:BPTH
Holding BPTH?
Track your performance easily
BPTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.59 - $12.00
Previous Close$1.26
Volume3.79M
Average Volume (3M)3.02M
Market Cap
$6.42M
Enterprise Value$2.47M
Total Cash (Recent Filing)$4.00M
Total Debt (Recent Filing)$55.00K
Price to Earnings (P/E)―
Beta-0.52
Next Earnings
Mar 07, 2025EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding4,306,892
10 Day Avg. Volume11,642,653
30 Day Avg. Volume3,016,672
Standard Deviation0.22
R-Squared0.00289
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)4.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bio-Path Holdings News
PremiumCompany Announcements
Bio-Path Holdings: Promising Preclinical Results for BP1001-A
PremiumCompany Announcements
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes
PremiumCompany Announcements
Bio-Path Holdings Shifts Focus to Metabolic Program
PremiumCompany Announcements
Bio-Path Holdings Expands DNAbilize® Technology Applications
PremiumPre-Earnings
Is BPTH a Buy, Before Earnings?Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.59 and its highest was $12.00 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Currently, no data Available
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Mar 07, 2025 which is in 76 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on Nov 15, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$1.02 by $0.32.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate is -$0.37.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 4,306,892 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.7 in its last earnings report, beating expectations of -$1.02. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
---
Bio-Path Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.9%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.07%
12-Months-Change
Fundamentals
Return on Equity
-1159.74%
Trailing 12-Months
Asset Growth
-40.95%
Trailing 12-Months
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
---
BPTH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Read More>---
BPTH Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering BPTH
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-52.84%
reiterated a buy rating 4 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.84% per trade.
---